INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
7.77
-0.30 (-3.72%)
At close: Apr 3, 2025, 4:00 PM
7.74
-0.03 (-0.44%)
Pre-market: Apr 4, 2025, 4:05 AM EDT
INmune Bio Employees
As of December 31, 2023, INmune Bio had 17 total employees, including 11 full-time and 6 part-time employees. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$824
Profits / Employee
-$2,475,412
Market Cap
178.17M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INMB News
- 7 days ago - INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - GlobeNewsWire
- 13 days ago - Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha
- 16 days ago - INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results - Seeking Alpha
- 7 weeks ago - INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - GlobeNewsWire
- 7 weeks ago - INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewsWire
- 3 months ago - INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha
- 3 months ago - INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers - Seeking Alpha